Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 7244Neoplasms 4539Prostatic Neoplasms 3489Colorectal Neoplasms 2940Carcinoma, Non-Small-Cell Lung 2831Lung Neoplasms 2547Leukemia, Myeloid, Acute 1982Pancreatic Neoplasms 1874Multiple Myeloma 1811Carcinoma, Hepatocellular 1733Neoplasm Metastasis 1585Stomach Neoplasms 1502Lymphoma 1457Precursor Cell Lymphoblastic Leukemia-Lymphoma 1435Head and Neck Neoplasms 1435Brain Neoplasms 1373Melanoma 1348Ovarian Neoplasms 1342Leukemia 1303Rectal Neoplasms 1270Recurrence 1255Colonic Neoplasms 1204Glioblastoma 1138Uterine Cervical Neoplasms 1096Lymphoma, Non-Hodgkin 1066Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 965Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 932Squamous Cell Carcinoma of Head and Neck 921

Interventions

Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × Small Cell Lung Cancer Recurrent × Clear all
NCT03823118 2023-02-23

S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

Taizhou Hospital

Phase 2 Completed
48 enrolled
Thoracic

Small Cell Lung Cancer Recurrent

NCT02477813 2018-11-13

TeRes

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated
6 enrolled
Thoracic

Small Cell Lung Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡